With this in mind, the targeting of iTAP/Frmd8 may be an appealing potential strategy to target ADAM17 activity in specific compartments during chronic inflammatory diseases or cancer, while avoiding collateral impact on the vital functions of ADAM17 in normal tissues. This evidence concerns the gene ADAM17 and cancer.